Metis TechBio Co (FRA:RO9) Other Current Liabilities: €8.09 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RO9 Metis TechBio Co Ltd FRA:RO9
17 GF Score
Price €1.31
! 1 Warning Sign
View Full Analysis

What is Metis TechBio Co Other Current Liabilities?

Metis TechBio Co FRA:RO9 +2.10% 17 Other Current Liabilities is €8.09 Mil as of Dec. 2025. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Metis TechBio Co's other current liabilities for the quarter that ended in Dec. 2025 was €8.09 Mil.

Metis TechBio Co's quarterly other current liabilities increased from Dec. 2024 (€8.15 Mil) to Sep. 2025 (€8.42 Mil) but then declined from Sep. 2025 (€8.42 Mil) to Dec. 2025 (€8.09 Mil).

Metis TechBio Co's annual other current liabilities increased from Dec. 2023 (€1.97 Mil) to Dec. 2024 (€8.15 Mil) but then declined from Dec. 2024 (€8.15 Mil) to Dec. 2025 (€8.09 Mil).

Metis TechBio Co Other Current Liabilities Related Terms

Metis TechBio Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Metis TechBio Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metis TechBio Co Other Current Liabilities Chart

Metis TechBio Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
1.95 1.97 8.15 8.09

Metis TechBio Co Quarterly Data
Dec22 Dec23 Dec24 Sep25 Dec25
Other Current Liabilities 1.95 1.97 8.15 8.42 8.09
FRA:RO9
17GF Score
Metis TechBio Co Ltd FRA:RO9
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metis TechBio Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €8.09 Mil mean?
Metis TechBio Co (FRA:RO9) has a Other Current Liabilities of €8.09 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metis TechBio Co.
Is Metis TechBio Co's Other Current Liabilities too high?
Metis TechBio Co's current Other Current Liabilities is €8.09 Mil. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Other Current Liabilities compare to VRTX and REGN?
Metis TechBio Co's Other Current Liabilities of €8.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metis TechBio Co. Metis TechBio Co's current Other Current Liabilities is €8.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Other Current Liabilities of €8.09 Mil. The current Other Current Liabilities is €8.09 Mil. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Other Current Liabilities is €8.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metis TechBio Co Business Description

Other Exchanges 07666:Hong Kong
Address No. 21 Tianhe West Road, Room 201, 2nd Floor, Building 13, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing, CHN
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score

Get the complete analysis for FRA:RO9

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price